From GlobeNewswire: 2025-03-05 07:02:00

Ocugen, Inc. reported positive 2-year data for OCU400 in treating retinitis pigmentosa, showing a significant improvement in visual function. They also completed dosing in the Phase 2 ArMaDa trial for geographic atrophy with favorable safety results. The company has aligned with the FDA for a Phase 2/3 trial for OCU410ST for Stargardt disease, potentially expediting clinical development by 2-3 years. Financially, Ocugen secured $65 million in equity/debt financing and is on track to meet recruitment goals for potential BLA/MAA filings by mid-2026. Additionally, the company’s inhaled mucosal vaccine for COVID-19, OCU500, received IND clearance from the FDA.



Read more at GlobeNewswire: Ocugen Provides Business Update with Fourth Quarter and